ALKS
Alkermes PlcNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$5.68B
P/E Ratio
23.83
EPS
$1.43
Beta
0.39
52W High
$36.48
52W Low
$25.17
50-Day MA
$31.42
200-Day MA
$29.75
Dividend Yield
—
Profit Margin
16.40%
Forward P/E
151.52
PEG Ratio
1.96
About Alkermes Plc
Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.
Fundamentals
| Revenue (TTM) | $1.48B |
| Gross Profit (TTM) | $1.28B |
| EBITDA | $281.12M |
| Operating Margin | 15.10% |
| Return on Equity | 14.70% |
| Return on Assets | 6.99% |
| Revenue/Share (TTM) | $8.96 |
| Book Value | $10.99 |
| Price-to-Book | 3.19 |
| Price-to-Sales (TTM) | 3.85 |
| EV/Revenue | 3.583 |
| EV/EBITDA | 15.98 |
| Quarterly Earnings Growth (YoY) | -67.00% |
| Quarterly Revenue Growth (YoY) | -10.60% |
| Shares Outstanding | $166.65M |
| Float | $154.04M |
| % Insiders | 1.60% |
| % Institutions | 110.28% |
Analyst Ratings
Consensus ($43.71 target)
3
Strong Buy12
Buy3
HoldData last updated: 4/7/2026